Contemporary Management Of Stage T1 Transitional Cell Carcinoma Of The Bladder
- 1 April 2002
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- p. 1573-1583
- https://doi.org/10.1097/00005392-200204000-00003
Abstract
No abstract availableThis publication has 97 references indexed in Scilit:
- SECOND RESECTION AND PROGNOSIS OF PRIMARY HIGH RISK SUPERFICIAL BLADDER CANCER: IS CYSTECTOMY OFTEN TOO EARLY?Journal of Urology, 2001
- P53 MUTATIONS IN BLADDER TUMORS INACTIVATE THE TRANSACTIVATION OF THE P21 AND BAX GENES, AND HAVE A PREDICTIVE VALUE FOR THE CLINICAL OUTCOME AFTER BACILLUS CALMETTE-GUERIN THERAPYJournal of Urology, 1999
- RESULTS OF A RANDOMIZED PHASE III TRIAL OF SEQUENTIAL INTRAVESICAL THERAPY WITH MITOMYCIN C AND BACILLUS CALMETTE-GUERIN VERSUS MITOMYCIN C ALONE IN PATIENTS WITH SUPERFICIAL BLADDER CANCERJournal of Urology, 1998
- Long-term survival of patients with bladder tumours: the significance of risk factorsBJU International, 1998
- CORRELATION BETWEEN p53 OVER EXPRESSION AND RESPONSE TO BACILLUS CALMETTE-GUERIN THERAPY IN A HIGH RISK SELECT POPULATION OF PATIENTS WITH T1G3 BLADDER CANCERJournal of Urology, 1998
- A Randomized Prospective Study Comparing Long-Term Intravesical Instillations of Mitomycin C and Bacillus Calmette-Guerin in Patients with Superficial Bladder CarcinomaJournal of Urology, 1996
- Alternating Mitomycin C and Bacillus Calmette-Guerin Instillation Prophylaxis For Recurrent Papillary (Stages Ta to T1) Superficial Bladder CancerJournal of Urology, 1996
- Reassessment of Conservative Management for Stage T1N0M0 Transitional Cell Carcinoma of the BladderJournal of Urology, 1996
- Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapyCancer, 1994
- Interleukin-2 production during intravesical bacille Calmette-Guerin therapy for bladder cancerClinical Immunology and Immunopathology, 1986